Citation, DOI, disclosures and article data
Citation:
Iqbal S, Gaillard F, Sharma R, et al. Acquired lipodystrophy. Reference article, Radiopaedia.org (Accessed on 31 Mar 2025) https://doi.org/10.53347/rID-80591
Disclosures:
At the time the article was last revised Frank Gaillard had the following disclosures:
- Biogen Australia Pty Ltd, Investigator-Initiated Research Grant for CAD software in multiple sclerosis: finished Oct 2021 (past)
These were assessed during peer review and were determined to
not be relevant to the changes that were made.
View Frank Gaillard's current disclosures
Acquired lipodystrophy is defined by the loss of body fat, insulin resistance and metabolic profile derangement. Subtypes include Barraquer-Simons syndrome, localised lipodystrophy and Lawrence syndrome. Lipodystrophy is illustrated as a complete or partial loss of adipose tissues from the body.
Overactivation of the complement system has been documented in most cases of acquired lipodystrophy 4. The condition is often seen in patients on certain medications including older antiretroviral agents for HIV (see HIV-associated lipodystrophy) disease but may also be seen in some autoimmune diseases or be idiopathic.
Whole-body MR is the modality of preference to see the pattern of fat loss (and in some cases concurrent regional lipomatosis) in acquired lipodystrophy.
Treatment and prognosis
A multidisciplinary therapeutic strategy includes counselling, metreleptin (recombinant leptin) 6, symptomatic treatment and managing any underlying primary disease.
-
1. Garg A. Acquired and inherited lipodystrophies. (2004) The New England journal of medicine. 350 (12): 1220-34. doi:10.1056/NEJMra025261 - Pubmed
-
2. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy. (2002) The New England journal of medicine. 346 (8): 570-8. doi:10.1056/NEJMoa012437 - Pubmed
-
3. Jehl A, Jehl CAC, Jehl VC, Jehl LA, Jehl DS, Jehl HO, Jehl ML, Jehl LO, Jehl CC, Jehl TC, Jehl LM, Jehl DE, Jehl. Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes. (2019) Diabetes care. doi:10.2337/dc18-2535 - Pubmed
-
4. Corvillo F, Corvillo AB, Corvillo. An overview of lipodystrophy and the role of the complement system. (2019) Molecular immunology. doi:10.1016/j.molimm.2019.05.011 - Pubmed
-
5. Hussain I, Hussain GA, Hussain. Lipodystrophy Syndromes. (2016) Endocrinology and metabolism clinics of North America. doi:10.1016/j.ecl.2016.06.012 - Pubmed
-
6. Nagayama, Ayako, Ashida, Kenji, Moritaka, Kanoko, Hidaka, Mami, Gobaru, Mizuki, Tanaka, Seiji, Hasuzawa, Nao, Akasu, Shoko, Goto, Yuka, Motomura, Seiichi, Hara, Kento, Tsuruta, Munehisa, Wada, Nobuhiko, Nakayama, Hitomi, Tajiri, Yuji, Nomura, Masatoshi. Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report. (2019) Journal of the Endocrine Society. 3 (11): 2179. doi:10.1210/js.2019-00251 - Pubmed
-
7. Ara jVD, Ara SF, Ara. Diagnosis and treatment of lipodystrophy: a step-by-step approach. (2019) Journal of endocrinological investigation. doi:10.1007/s40618-018-0887-z - Pubmed
Promoted articles (advertising)
Unable to process the form. Check for errors and try again.